|
BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer
|
In the RATIONALE 305 trial, tislelizumab combined with chemotherapy prolonged overall survival for patients with PD-L1 expression Additional follow-up is needed to assess overall survival benefits in intention-to-treat patient population Safety fin...
Full "IntellAsia: Resources" article
|
|